

CENTER FOR DRUG EVALUATION AND RESEARCH

Application Number **20 - 869**

MICROBIOLOGY REVIEW(S)

H0
550

NOV 6 1997

REVIEW FOR HFD-550
OFFICE OF NEW DRUG CHEMISTRY
MICROBIOLOGY STAFF, HFD-805
MICROBIOLOGIST'S REVIEW No. 1 OF NDA

6 November 1997

A. 1. NDA **20-869**

APPLICANT Merck Research Laboratories
Sumneytown Pike, P.O. Box 4, BLA-20
West Point, PA 19486

2. PRODUCT NAMES: COSOPT® (Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution)

3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: COSOPT Ophthalmic Solution is a clear, colorless to nearly colorless, slightly viscous solution. No. 3628 — COSOPT Ophthalmic Solution is supplied in an OCUMETER®, a white, opaque, plastic ophthalmic dispenser with a controlled drop tip as follows:

5 mL,
10 mL.

4. METHOD(S) OF STERILIZATION:

5. PHARMACOLOGICAL CATEGORY: COSOPT is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure by reducing aqueous humor secretion, but by different mechanisms of action.

6. DRUG PRIORITY CLASSIFICATION: 4S

B. 1. DATE OF INITIAL SUBMISSION: 10 July 1997

2. DATE OF AMENDMENT: 9 July 1997

3. RELATED DOCUMENTS:


NDA 20-408 (Sterile Ophthalmic Solution
TRUSOPT®, Dorzolamide hydrochloride, NDA 18-086 (Sterile Ophthalmic
Solution TIMOPTIC®).

4. ASSIGNED FOR REVIEW: 18 July 1997

- C. REMARKS: The application provides for a new drug product which is a combination of 2 previously approved products. HFD-550 has provided volumes 1.1, 1.2, and the Amendment of 9 July 1997 which contains the microbiology section. An electronic form of this NDA has been provided over the CDER network.
- D. CONCLUSIONS: The submission is approvable. Comments are provided in the "Microbiologist's List of Comments and Deficiencies."

11-06-97

David Hussong, Ph.D.

 11/6/97

cc:

HFD-160/Consult File
HFD-550/CSO/Gorski
HFD-550/Chemist/Ho
HFD-805/D. Hussong

Drafted by: D. Hussong, 10/15/97
R/D initialed by: P. Cooney

Filename, c:\d\nda\20-869r1.wpd

C-Orsk
550

REVIEW FOR HFD-550
OFFICE OF NEW DRUG CHEMISTRY
MICROBIOLOGY STAFF, HFD-805
MICROBIOLOGIST'S REVIEW No. 1 OF NDA

6 November 1997

A. 1. NDA **20-869**

APPLICANT Merck Research Laboratories
Sumneytown Pike, P.O. Box 4, BLA-20
West Point, PA 19486

2. PRODUCT NAMES: COSOPT® (Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution)
3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: COSOPT Ophthalmic Solution is a clear, colorless to nearly colorless, slightly viscous solution. No. 3628 — COSOPT Ophthalmic Solution is supplied in an OCUMETER®, a white, opaque, plastic ophthalmic dispenser with a controlled drop tip as follows:
- 5 mL,
10 mL.
4. METHOD(S) OF STERILIZATION: Aseptic processing
5. PHARMACOLOGICAL CATEGORY: COSOPT is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure by reducing aqueous humor secretion, but by different mechanisms of action.
6. DRUG PRIORITY CLASSIFICATION: 4S

B. 1. DATE OF INITIAL SUBMISSION: 10 July 1997

2. DATE OF AMENDMENT: 9 July 1997

3. RELATED DOCUMENTS:


NDA 20-408 (Sterile Ophthalmic Solution
TRUSOPT®, Dorzolamide hydrochloride, NDA 18-086 (Sterile Ophthalmic
Solution TIMOPTIC®).

4. ASSIGNED FOR REVIEW: 18 July 1997

- C. REMARKS: The application provides for a new drug product which is a combination of 2 previously approved products. HFD-550 has provided volumes 1.1, 1.2, and the Amendment of 9 July 1997 which contains the microbiology section. An electronic form of this NDA has been provided over the CDER network.
- D. CONCLUSIONS: The submission is approvable. Comments are provided in the "Microbiologist's List of Comments and Deficiencies."

11-06-97

David Hussong, Ph.D.

 11/6/97

cc:

HFD-160/Consult File
HFD-550/CSO/Gorski
HFD-550/Chemist/Ho
HFD-805/D. Hussong

Drafted by: D. Hussong, 10/15/97
R/D initialed by: P. Cooney

Filename, c:\d\nda\20-869r1.wpd

REVIEW FOR HFD-550
OFFICE OF NEW DRUG CHEMISTRY
MICROBIOLOGY STAFF, HFD-805
MICROBIOLOGIST'S REVIEW #2 OF NDA

6 April 1998

A. 1. NDA **20-869**

APPLICANT Merck Research Laboratories
Sumneytown Pike, P.O. Box 4, BLA-20
West Point, PA 19486

2. PRODUCT NAMES: COSOPT® (Dorzolamide Hydrochloride-Timolol Maleate Ophthalmic Solution)

3. DOSAGE FORM AND ROUTE OF ADMINISTRATION: COSOPT Ophthalmic Solution is a clear, colorless to nearly colorless, slightly viscous solution. No. 3628 — COSOPT Ophthalmic Solution is supplied in an OCUMETER®, a white, opaque, plastic ophthalmic dispenser with a controlled drop tip as follows:

5 mL,
10 mL.

4. METHOD(S) OF STERILIZATION: Aseptic processing

5. PHARMACOLOGICAL CATEGORY: COSOPT is comprised of two components: dorzolamide hydrochloride and timolol maleate. Each of these two components decreases elevated intraocular pressure by reducing aqueous humor secretion, but by different mechanisms of action.

6. DRUG PRIORITY CLASSIFICATION: 4S

B. 1. DATE OF INITIAL SUBMISSION: 10 July 1997


2. DATE OF AMENDMENT: 9 July 1997

3. RELATED DOCUMENTS: Microbiologist's Review #1 (11/06/97),
NDA 20-408
(Sterile Ophthalmic Solution TRUSOPT®, Dorzolamide hydrochloride, NDA 18-086 (Sterile Ophthalmic Solution TIMOPTIC®).

4. ASSIGNED FOR REVIEW: March 9, 1998

- C. REMARKS: The application provides for a new drug product which is a combination of 2 previously approved products. In the current submission, the applicant replies to questions conveyed in a facsimile dated June 25, 1997. Microbiology issues (from Microbiologist's Review #1) were conveyed in questions 11 and 12 of that communication. Since the subject drug is a combination of currently marketed products, there is little likelihood of a microbiology hazard associated with the manufacture of this product. However, several critical controls and processes were inadequately described and needed to be made clear in the application file.
- D. CONCLUSIONS: The submission is recommended for approval.

4-6-98

David Hussong, Ph.D. 4/6/98

cc:

HFD-160/Consult File
HFD-550/CSO/Gorski
HFD-550/Chemist/Ho
HFD-805/D. Hussong

Drafted by: D. Hussong, 04/03/98
R/D initialed by: P. Cooney

Filename, c:\d\nda\20-869r2.wpd